Abstract
Peroxisome proliferator-activated receptors (PPARs) are key players in lipid and glucose metabolism and are implicated in metabolic disorders predisposing to atherosclerosis, such as dyslipidaemia and diabetes1. Whereas PPARγ promotes lipid storage by regulating adipocyte differentiation, PPARα stimulates the β-oxidative degradation of fatty acids. PPARα-deficient mice show a prolonged response to inflammatory stimuli, suggesting that PPARα is also a modulator of inflammation2. Hypolipidaemic fibrate drugs are PPARα ligands that inhibit the progressive formation of atherosclerotic lesions, which involves chronic inflammatory processes3, even in the absence of their atherogenic lipoprotein-lowering effect4,5. Here we show that PPARα is expressed in human aortic smooth-muscle cells, which participate in plaque formation and post-angioplasty re-stenosis3. In these smooth-muscle cells, we find that PPARα ligands, and not PPARγ ligands, inhibit interleukin-1-induced production of interleukin-6 and prostaglandin and expression of cyclooxygenase-2. This inhibition of cyclooxygenase-2 induction occurs transcriptionally as a result of PPARα repression of NF-κB signalling. In hyperlipidaemic patients, fenofibrate treatment decreases the plasma concentrations of interleukin-6, fibrinogen and C-reactive protein. We conclude that activators of PPARα inhibit the inflammatory response of aortic smooth-muscle cells and decrease the concentration of plasma acute-phase proteins, indicating that PPARα in the vascular wall may influence the process of atherosclerosis and re-stenosis.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Schoonjans, K., Martin, G., Staels, B. & Auwerx, J. Peroxisome proliferator-activated receptors, orphans with ligands and functions. Curr. Opin. Lipidol. 8, 159–166 (1997).
Devchand, P. R. et al. The PPARα-leukotriene B4 pathway to inflammation control. Nature 384, 39–43 (1996).
Ross, R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362, 801–809 (1993).
Saitoh, K. et al. Anti-atheromatous effects of fenofibrate, a hypolipidemic drug. I: Anti-atheromatous effects are independent of its hypolipidemic effect in cholesterol-fed rabbits. Folia Pharmacol. Japon. 106, 41–50 (1995).
Ericsson, C. G. et al. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 347, 849–853 (1996).
Auboeuf, D. et al. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-α in humans. No alterations in adipose tissue of obese and NIDDM patients. Diabetes 46, 1319–1327 (1997).
Loppnow, H. & Libby, P. Proliferating or interleukin-1 activated human vascular smooth muscle cells secrete copious interleukin 6. J. Clin. Invest. 85, 731–738 (1990).
Forman, B. M., Chen, J. & Evans, R. M. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ. Proc. Natl Acad. Sci. USA 94, 4312–4317 (1997).
Vu-Dac, N. et al. Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. J. Clin. Invest. 96, 741–750 (1995).
Balfour, J. A., McTavish, D. & Heel, R. C. Fenofibrate, a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia. Drugs 40, 260–290 (1990).
Todd, P. A. & Ward, A. Gemfibrozil, a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in dyslipidaemia. Drugs 36, 314–339 (1988).
Lehmann, J. M. et al. An antidiabetic thiazolidinedione is a high affinity ligand for Peroxisome Proliferator-Activated Receptor γ (PPARγ). J. Biol. Chem. 270, 12953–12956 (1995).
Newton, R., Kuitert, L. M. E., Bergmann, M., Adcock, I. M. & Barnes, P. J. Evidence for involvement of NF-κB in the transcriptional control of COX-2 gene expression by IL-1β. Biochem. Biophys. Res. Commun. 237, 28–32 (1997).
Kutchera, W. et al. Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: evidence for a transcriptional effect. Proc. Natl Acad. Sci. USA 93, 4816–4820 (1996).
Xie, W. & Herschman, H. R. Transcriptional regulation of prostaglandin synthase 2 gene expression by platelet-derived growth factor and serum. J. Biol. Chem. 271, 31742–31748 (1996).
Yamamoto, K., Arakawa, T., Ueda, N. & Yamamoto, S. Transcriptional roles of nuclear factor κB and nuclear factor-interleukin-6 in the tumor necrosis factor α-dependent induction of cyclooxygenase-2 in MC3T3-E1 cells. J. Biol. Chem. 270, 31315–31320 (1995).
Liuzzo, G. et al. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N. Engl. J. Med. 331, 417–424 (1994).
Thompson, S. G., Kienast, J., Pyke, S. D. M., Haverkate, F. & van de Loo, J. C. W. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N. Engl. J. Med. 332, 635–641 (1995).
Ricote, M., Li, A. C., Willsson, T. M., Kelly, C. J. & Glass, C. K. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 391, 79–82 (1998).
Jiang, C., Ting, A. T. & Seed, B. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature 391, 82–86 (1998).
Galis, Z. S., Sukhova, G. K., Lark, M. W. & Libby, P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J. Clin. Invest. 94, 2493–2503 (1994).
Brand, K. et al. Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion. J. Clin. Invest. 97, 1715–1722 (1996).
Bourcier, T., Sukhova, G. & Libby, P. The nuclear factor κ-B signalling pathway participates in dysregulation of vascular smooth muscle cells in vitro and in human atherosclerosis. J. Biol. Chem. 272, 15817–15824 (1997).
Rich, B. E. & Steitz, J. A. Human acidic ribosomal phosphoprotein P0, P1 and P2: analysis of cDNA clones, in vitro synthesis and assembly. Mol. Cell. Biol. 7, 4065–4074 (1987).
Soriano, P., Montgomery, C., Geske, R. & Bradley, A. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 64, 693–702 (1991).
Clauss, A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol. 17, 237–246 (1957).
Belmin, J. et al. Increased production of tumor necrosis factor and interleukin 6 by the arterial wall of aged rats. Am. J. Physiol. 268, H2288–H2293 (1995).
Pradelles, P., Grassi, J. & Maclouf, J. Enzyme immunoassay of eicosanoids using acetylcholine esterase as label: an alternative to radioimmunoassay. Analyt. Chem. 57, 1170–1173 (1985).
Habib, A. et al. Demonstration of an inducible cyclooxygenase in human endothelial cells using antibodies raised against the carboxyl-terminal region of the cyclooxygenase-2. J. Biol. Chem. 268, 23448–23454 (1993).
Jones, D. A., Carlton, D. P., McIntyre, M. P., Zimmerman, G. A. & Prescott, S. M. Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines. J. Biol. Chem. 268, 9049–9054 (1993).
Acknowledgements
We acknowledge the technical contribution of O. Vidal, P. Poulain and B. Derudas, and thank C. Haegeman for p50 and p65/RelA, S. Prescott for human COX-2 promoter plasmids, and M. Sund for help with statistical analysis. This work was supported by grants from the Association pour la Recherche sur le Cancer (to J.M.), CNAMTS/INSERM (to A.T.) and the Région Nord-Pas de Calais. B.S. and J.M. are members of the CNRS.
Author information
Authors and Affiliations
Corresponding author
Supplementary Information
Rights and permissions
About this article
Cite this article
Staels, B., Koenig, W., Habib, A. et al. Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators. Nature 393, 790–793 (1998). https://doi.org/10.1038/31701
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/31701
This article is cited by
-
Gemfibrozil Alleviates Cognitive Impairment by Inhibiting Ferroptosis of Astrocytes via Restoring the Iron Metabolism and Promoting Antioxidant Capacity in Type 2 Diabetes
Molecular Neurobiology (2024)
-
Impaired autophagy contributes to the aggravated deterioration of osteoarthritis articular cartilage by peroxisome proliferator-activated receptor α deficiency, associated with decreased ERK and Akt activation
European Journal of Medical Research (2023)
-
An insight to treat cardiovascular diseases through phytochemicals targeting PPAR-α
Molecular and Cellular Biochemistry (2023)
-
Fibroblast Growth Factor 21 Ameliorates Endothelin I-Induced Hypertension Partly Through PPAR γ Pathway
International Journal of Peptide Research and Therapeutics (2022)
-
Probiotic Bifidobacterium lactis V9 attenuates hepatic steatosis and inflammation in rats with non-alcoholic fatty liver disease
AMB Express (2020)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.